Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16305497 | 0.88 | HRH3 (0.40) | HRH3OPRK1NPC1 | |
| SCHEMBL15995518 | 0.88 | HRH3 (0.40) | HRH3OPRK1NPC1 | |
| SCHEMBL16293500 | 0.88 | KDM5B (0.36) | TERTSMN1; SMN2RXFP1 | |
| SCHEMBL16006940 | 0.88 | KDM5B (0.36) | TERTSMN1; SMN2RXFP1 | |
| SCHEMBL16006922 | 0.78 | HRH3 (0.43) | HRH3OPRK1NPC1 | |
| SCHEMBL15994366 | 0.75 | KDM5B (0.41) | — | |
| SCHEMBL16305471 | 0.74 | MEN1 (0.41) | HRH3KCNH2SMN1; SMN2 | |
| SCHEMBL15995289 | 0.74 | MEN1 (0.41) | HRH3KCNH2SMN1; SMN2 | |
| SCHEMBL16293826 | 0.73 | APP (0.35) | SMN1; SMN2RXFP1 | |
| SCHEMBL17365406 | 0.73 | KDM4E (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | TERT 1180/4885HRH3 269/4885FAP 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.